Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data Multiple myeloma (MM), the second ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose ...

Researchers conducted an analysis of how NCCN guidelines for myeloma treatment are updated, offering suggestions for a more standardized process.

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...

Oncologist David Chung is taking on Northwell Health's newly established role of director of clinical research at its cancer ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...